• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

牛乳头瘤病毒样颗粒展示了 HIV-1 gp41 膜近端外部区域的保守表位,诱导了黏膜和系统抗体。

Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.

机构信息

Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, United States.

出版信息

Vaccine. 2013 Nov 4;31(46):5422-9. doi: 10.1016/j.vaccine.2013.09.003. Epub 2013 Sep 19.

DOI:10.1016/j.vaccine.2013.09.003
PMID:24055348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3881962/
Abstract

Two conserved epitopes, located in the membrane-proximal external region (MPER) of the human immunodeficiency virus type 1 (HIV-1) gp41, are recognized by two HIV-1 broadly neutralizing antibodies 2F5 and 4E10, and are promising targets for vaccine design in efforts to elicit anti-HIV-1 broadly neutralizing antibodies. Since most HIV-1 infections initiate at mucosal surfaces, induction of mucosal neutralizing antibodies is necessary and of utmost importance to counteract HIV-1 infection. Here, we utilized a mucosal vaccine vector, bovine papillomavirus (BPV) virus-like particles (VLPs), as a platform to present HIV-1 neutralizing epitopes by inserting the extended 2F5 or 4E10 epitope or the MPER domain into D-E loop of BPV L1 respectively. The chimeric VLPs presenting MPER domain resembled the HIV-1 natural epitopes better than the chimeric VLPs presenting single epitopes. Oral immunization of mice with the chimeric VLPs displaying the 2F5 epitope or MPER domain elicited epitope-specific serum IgGs and mucosal secretory IgAs. The induced antibodies specifically recognized the native conformation of MPER in the context of HIV-1 envelope protein. The antibodies induced by chimeric VLPs presenting MPER domain are able to partially neutralize HIV-1 viruses from clade B and clade C.

摘要

两个保守表位位于人类免疫缺陷病毒 1 型(HIV-1)gp41 的膜近端外部区域(MPER),被两种 HIV-1 广泛中和抗体 2F5 和 4E10 识别,是设计疫苗以诱导抗 HIV-1 广泛中和抗体的有希望的靶点。由于大多数 HIV-1 感染始于黏膜表面,诱导黏膜中和抗体对于抵抗 HIV-1 感染是必要的,也是至关重要的。在这里,我们利用黏膜疫苗载体牛乳头瘤病毒(BPV)病毒样颗粒(VLPs)作为平台,通过将扩展的 2F5 或 4E10 表位或 MPER 结构域分别插入 BPV L1 的 D-E 环,来展示 HIV-1 中和表位。展示 MPER 结构域的嵌合 VLPs 比展示单个表位的嵌合 VLPs 更能模拟 HIV-1 天然表位。用展示 2F5 表位或 MPER 结构域的嵌合 VLPs 对小鼠进行口服免疫,可诱导出表位特异性血清 IgG 和黏膜分泌型 IgA。诱导的抗体特异性识别 HIV-1 包膜蛋白背景下的天然 MPER 构象。展示 MPER 结构域的嵌合 VLPs 诱导的抗体能够部分中和来自 B 族和 C 族的 HIV-1 病毒。

相似文献

1
Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies.牛乳头瘤病毒样颗粒展示了 HIV-1 gp41 膜近端外部区域的保守表位,诱导了黏膜和系统抗体。
Vaccine. 2013 Nov 4;31(46):5422-9. doi: 10.1016/j.vaccine.2013.09.003. Epub 2013 Sep 19.
2
Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein.基于病毒样颗粒(VLP)的免疫原的开发及其对暴露HIV-1 gp41蛋白膜近端区域的免疫评估
J Biomed Sci. 2014 Aug 27;21(1):79. doi: 10.1186/s12929-014-0079-x.
3
Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.1型人类免疫缺陷病毒gp41膜近端外部区域排列在乙型肝炎表面抗原颗粒上的分析。
Virology. 2008 Mar 30;373(1):72-84. doi: 10.1016/j.virol.2007.11.005. Epub 2007 Dec 26.
4
Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.通过口服牛乳头瘤病毒-1型人类免疫缺陷病毒(HIV-1)gp41嵌合病毒样颗粒诱导针对HIV-1的黏膜和全身中和抗体。
J Virol. 2004 Aug;78(15):8342-8. doi: 10.1128/JVI.78.15.8342-8348.2004.
5
Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.抗1型人类免疫缺陷病毒(HIV-1)抗体2F5和4E10在糖蛋白gp41的膜近端外部区域只需极少关键残基就能中和HIV-1。
J Virol. 2005 Jan;79(2):1252-61. doi: 10.1128/JVI.79.2.1252-1261.2005.
6
Development of a DNA vaccine expressing a secreted HIV-1 gp41 ectodomain that includes the membrane-proximal external region.一种表达分泌型HIV-1 gp41胞外结构域(包括膜近端外部区域)的DNA疫苗的研发。
Vaccine. 2017 May 9;35(20):2736-2744. doi: 10.1016/j.vaccine.2017.03.039. Epub 2017 Apr 6.
7
Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants.口服柯萨奇病毒 B4 重组体诱导黏膜 HIV 特异性 B 和 T 细胞应答。
Vaccine. 2012 May 21;30(24):3666-74. doi: 10.1016/j.vaccine.2012.03.034. Epub 2012 Mar 29.
8
Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen.多个串联的保守 gp41 表位被整合到 gag 病毒样颗粒中,在优化的异源载体传递方案中诱导系统和黏膜抗体。
Vaccine. 2010 Oct 8;28(43):7070-80. doi: 10.1016/j.vaccine.2010.08.009. Epub 2010 Aug 17.
9
N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.人类免疫缺陷病毒1型糖蛋白41膜近端外部区域抗原的N端残基影响广谱中和性2F5样抗体。
Virol Sin. 2015 Dec;30(6):449-56. doi: 10.1007/s12250-015-3664-6. Epub 2015 Dec 21.
10
Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines.通过基于 HA/gp41 嵌合蛋白的 DNA 和 VLP 疫苗诱导针对 HIV 包膜蛋白 MPER 的中和抗体。
PLoS One. 2011;6(5):e14813. doi: 10.1371/journal.pone.0014813. Epub 2011 May 19.

引用本文的文献

1
Molecular Analysis and Bioinformatics Assessment of Full-Length L1 Gene of Bovine Papillomavirus Type-1 as a Potential DNA Vaccine Study.牛乳头瘤病毒1型全长L1基因作为潜在DNA疫苗研究的分子分析与生物信息学评估
Vet Med Int. 2025 Apr 10;2025:6785087. doi: 10.1155/vmi/6785087. eCollection 2025.
2
Chimeric Human Papillomavirus-16 Virus-like Particles Presenting HIV-1 P18I10 Peptide: Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice.嵌合型人乳头瘤病毒 16 病毒样颗粒展示 HIV-1 P18I10 肽:在 BALB/c 小鼠中的表达、纯化、生物物理特性和免疫原性。
Int J Mol Sci. 2023 Apr 29;24(9):8060. doi: 10.3390/ijms24098060.
3

本文引用的文献

1
Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies.鉴定 2F5 和 4E10 广谱中和抗 HIV-1 抗体所识别的自身抗原。
J Exp Med. 2013 Feb 11;210(2):241-56. doi: 10.1084/jem.20121977. Epub 2013 Jan 28.
2
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody.一种 gp41 特异性人抗体对 HIV-1 的广泛而强效的中和作用。
Nature. 2012 Nov 15;491(7424):406-12. doi: 10.1038/nature11544. Epub 2012 Sep 18.
3
Virus like particle based strategy to elicit HIV-protective antibodies to the alpha-helic regions of gp41.
Chimeric Human Papillomavirus-16 Virus-like Particles Presenting P18I10 and T20 Peptides from HIV-1 Envelope Induce HPV16 and HIV-1-Specific Humoral and T Cell-Mediated Immunity in BALB/c Mice.
呈现来自HIV-1包膜的P18I10和T20肽的嵌合人乳头瘤病毒16型病毒样颗粒在BALB/c小鼠中诱导HPV16和HIV-1特异性体液免疫和T细胞介导的免疫。
Vaccines (Basel). 2022 Dec 21;11(1):15. doi: 10.3390/vaccines11010015.
4
Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies.通过增加膜近端外部区域导向的广谱中和抗体的局部浓度来增强 HIV-1 中和作用。
J Virol. 2023 Jan 31;97(1):e0164722. doi: 10.1128/jvi.01647-22. Epub 2022 Dec 21.
5
How promising are HIV-1-based virus-like particles for medical applications.基于 HIV-1 的病毒样颗粒在医学应用中前景如何。
Front Cell Infect Microbiol. 2022 Oct 7;12:997875. doi: 10.3389/fcimb.2022.997875. eCollection 2022.
6
Demystifying particle-based oral vaccines.解析基于粒子的口服疫苗。
Expert Opin Drug Deliv. 2021 Oct;18(10):1455-1472. doi: 10.1080/17425247.2021.1946511. Epub 2021 Jul 6.
7
Design Concepts of Virus-Like Particle-Based HIV-1 Vaccines.基于病毒样颗粒的 HIV-1 疫苗的设计理念。
Front Immunol. 2020 Sep 30;11:573157. doi: 10.3389/fimmu.2020.573157. eCollection 2020.
8
Neutralizing Antibodies Targeting HIV-1 gp41.靶向 HIV-1 gp41 的中和抗体。
Viruses. 2020 Oct 23;12(11):1210. doi: 10.3390/v12111210.
9
SnoopLigase peptide-peptide conjugation enables modular vaccine assembly.SnoopLigase 肽-肽偶联能够实现模块化疫苗组装。
Sci Rep. 2019 Mar 15;9(1):4625. doi: 10.1038/s41598-019-40985-w.
10
Synthetic biology for bioengineering virus-like particle vaccines.合成生物学在工程病毒样颗粒疫苗中的应用。
Biotechnol Bioeng. 2019 Apr;116(4):919-935. doi: 10.1002/bit.26890. Epub 2018 Dec 31.
基于病毒样颗粒的策略来诱导针对 gp41 的α-螺旋区的 HIV 保护性抗体。
Virology. 2012;431(1-2):1-11. doi: 10.1016/j.virol.2012.05.005. Epub 2012 Jun 2.
4
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.结构和深度测序揭示 HIV-1 中和抗体的定向进化。
Science. 2011 Sep 16;333(6049):1593-602. doi: 10.1126/science.1207532. Epub 2011 Aug 11.
5
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.分析 HIV-1 包膜 V2/V3 构象表位特异性广谱中和抗体的克隆谱系及其推断的未突变共同祖先。
J Virol. 2011 Oct;85(19):9998-10009. doi: 10.1128/JVI.05045-11. Epub 2011 Jul 27.
6
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.序列和结构上与 CD4 结合模拟广泛而有效的 HIV 抗体的趋同。
Science. 2011 Sep 16;333(6049):1633-7. doi: 10.1126/science.1207227. Epub 2011 Jul 14.
7
HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies.HIV-1 gp41 核心带有暴露的膜近端外部区域,诱导广泛的 HIV-1 中和抗体。
PLoS One. 2011 Mar 31;6(3):e18233. doi: 10.1371/journal.pone.0018233.
8
Lessons drawn from recent HIV vaccine efficacy trials.从最近的 HIV 疫苗功效试验中吸取的教训。
J Acquir Immune Defic Syndr. 2010 Dec;55 Suppl 2(Suppl 2):S128-31. doi: 10.1097/QAI.0b013e3181fbca02.
9
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.包膜的合理设计鉴定出针对 HIV-1 的广泛中和人源单克隆抗体。
Science. 2010 Aug 13;329(5993):856-61. doi: 10.1126/science.1187659. Epub 2010 Jul 8.
10
Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants.经佐剂增强的针对人乳头瘤病毒 16 L1 蛋白的舌下免疫的体液和细胞免疫应答。
Vaccine. 2010 Mar 19;28(14):2598-606. doi: 10.1016/j.vaccine.2010.01.013. Epub 2010 Jan 28.